Researchers showed that GSK-3484862 targets DNMT1 for protein degradation in both cancer cell lines and murine ESCs. DNMT1 depletion was rapid, taking effect within hours following GSK-3484862 treatment, leading to global hypomethylation.
[NAR Cancer]
